Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-2416 alone or with durvalumab in advanced malignancies
NCT03323398Phase 2Terminated
- Sponsor
- Moderna Inc
- Start
- Aug 2017
- Primary completion
- Aug 2021
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-2416 in solid tumor, lymphoma, ovarian cancer, sponsored by Moderna Inc. Started Aug 2017; status: terminated.
02
Drugs
mRNA-2416
03
Conditions
solid tumorlymphomaovarian cancer
Beyond the preview
Go deeper on NCT03323398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323398.